100,000 Shares in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Acquired by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC purchased a new stake in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 100,000 shares of the biopharmaceutical company’s stock, valued at approximately $289,000. Clear Harbor Asset Management LLC owned approximately 0.09% of AVEO Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Paloma Partners Management Co acquired a new position in shares of AVEO Pharmaceuticals during the first quarter valued at $184,000. UBS Oconnor LLC purchased a new position in AVEO Pharmaceuticals during the first quarter valued at $291,000. Sabby Management LLC purchased a new position in AVEO Pharmaceuticals during the first quarter valued at $513,000. Renaissance Technologies LLC boosted its position in AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares in the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in AVEO Pharmaceuticals during the first quarter valued at $1,711,000. 51.03% of the stock is owned by institutional investors.

AVEO Pharmaceuticals, Inc. (AVEO) opened at 3.03 on Friday. AVEO Pharmaceuticals, Inc. has a 52-week low of $0.50 and a 52-week high of $3.30. The company’s market capitalization is $358.47 million. The firm’s 50-day moving average is $2.63 and its 200-day moving average is $1.22.

COPYRIGHT VIOLATION WARNING: This piece was reported by [[site]] and is the property of of [[site]]. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at [[permalink]].

Several research firms recently weighed in on AVEO. Piper Jaffray Companies set a $2.00 target price on shares of AVEO Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 24th. BidaskClub raised shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. FBR & Co reissued an “outperform” rating and issued a $3.00 target price on shares of AVEO Pharmaceuticals in a research note on Monday, May 22nd. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, ValuEngine raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 24th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $3.08.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.